KRAKOW, Poland, April 25, 2025 / Biotech Newswire / --

波兰克拉科夫，2025年4月25日 /生物技术新闻社/ --

Ryvu Therapeutics

Ryvu治疗学

(WSE: RVU), a clinical-stage drug discovery and development company focusing on innovative therapies targeting emerging areas in oncology, is presenting preclinical data from its synthetic lethality pipeline at the 2025 AACR Annual Meeting, April 25 to April 30, 2025 in Chicago, IL. Additionally, the company will give an oral presentation on Ryvu’s ADC (antibody-drug conjugate) payload innovation at the 2nd ADC Payload Summit, May 6 to May 8, 2025, in Boston, MA..

（WSE：RVU），一家专注于肿瘤学新兴领域创新疗法的临床阶段药物发现与开发公司，将于2025年4月25日至30日在伊利诺伊州芝加哥举行的2025年AACR年会上展示其合成致死管线的临床前数据。此外，该公司还将在2025年5月6日至8日于马萨诸塞州波士顿举行的第二届ADC有效载荷峰会上，就Ryvu的ADC（抗体药物偶联物）有效载荷创新进行口头报告。

'We are excited to showcase continued progress across our preclinical pipeline. In particular, we are rapidly advancing RVU305, our potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, with IND/CTA-enabling studies on track for completion in H2 2025. In addition, our proprietary ONCO Prime platform has identified several novel synthetic lethal targets, including targets for KRAS-driven tumors, which offer immense potential to transform cancer treatment.

“我们很高兴展示我们在临床前管线中取得的持续进展。特别是，我们正在快速推进RVU305，这是我们潜在的同类最优、可透过血脑屏障的MTA协同PRMT5抑制剂，其IND/CTA支持性研究正按计划在2025年下半年完成。此外，我们专有的ONCO Prime平台已经识别出多个新的合成致死靶点，包括针对KRAS驱动肿瘤的靶点，这些靶点具有巨大的潜力来改变癌症治疗。

We are also developing innovative next-generation ADCs with new payload classes,.

我们还在开发具有新有效载荷类别的创新下一代ADC。

'

'

said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics.

Ryvu Therapeutics的首席科学官Krzysztof Brzózka博士说。

Details on poster presentations are as follows:

海报展示的详细信息如下：

Poster Title:

海报标题：

“Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment.

临床前候选药物RVU305是一种MTA协同的PRMT5抑制剂，在对免疫检查点治疗耐药的MTAP缺失肿瘤中显示出活性。

”

”

Session Name:

会话名称：

HDAC and Methyltransferase Inhibitors

HDAC和甲基转移酶抑制剂

Session date and time:

会话日期和时间：

Tuesday, April 29, 9:00 AM - 12:00 PM EST

4月29日星期二，上午9:00 - 下午12:00（东部时间）

Poster Number:

海报编号：

17

17

RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant potential in targeting MTAP-deleted cancers. In preclinical studies, RVU305 effectively inhibited tumor growth in MTAP-null cancer models without affecting normal cells. RVU305 also demonstrated CNS penetration with predicted efficacious exposure in the brain in cynomolgus monkeys.

RVU305 是一种潜在的同类最佳、可透过血脑屏障的 MTA 协同 PRMT5 抑制剂，在针对 MTAP 缺失型癌症方面展现了显著潜力。在临床前研究中，RVU305 在 MTAP 缺失的癌症模型中有效抑制了肿瘤生长，且未影响正常细胞。此外，RVU305 还表现出中枢神经系统渗透能力，并在食蟹猴脑部达到了预期的有效暴露水平。

In CNS cell lines, RVU305 exhibited high potency and efficacy. Furthermore, co-treatment with an anti-PD-1 antibody was well tolerated and resulted in antitumor activity in an MTAP-deleted model resistant to immune checkpoint inhibitors (ICI). The efficacy of RVU305 was supported by pharmacodynamic changes observed in tumor tissue.

在中枢神经系统细胞系中，RVU305表现出高效性和强效性。此外，与抗PD-1抗体联合治疗耐受性良好，并在对免疫检查点抑制剂（ICI）耐药的MTAP缺失模型中显示出抗肿瘤活性。RVU305的疗效得到了肿瘤组织中观察到的药效学变化的支持。

These results position RVU305 as a promising therapeutic option for patients carrying MTAP-deleted cancers resistant to ICI..

这些结果表明 RVU305 是携带 MTAP 缺失且对 ICI 耐药的癌症患者的一种有前景的治疗选择。

Poster Title:

海报标题：

“Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies.

“发现新的合成致死靶点以实现有效且安全的结直肠癌治疗。”

”

”

Session Name:

会话名称：

Experimental and Molecular Therapeutics

实验和分子治疗学

Session date and time:

会话日期和时间：

Monday, April 28, 2:00 PM - 5:00 PM EST

4月28日星期一，下午2:00 - 下午5:00（东部时间）

Poster Number:

海报编号：

3

3

This study highlights the discovery and validation of novel therapeutic targets for colorectal cancer (CRC) through synthetic lethal (SL) interactions, addressing the urgent need for more effective and personalized treatment options. The team identified key vulnerabilities in CRC using advanced models, including genetically engineered human intestinal stem cells (hISCs) and patient-derived xenografts (PDXs) in combination with CRISPR/Cas9 technology..

本研究通过合成致死（SL）相互作用，发现了结直肠癌（CRC）的新治疗靶点并进行了验证，满足了对更有效和个性化治疗方案的迫切需求。研究团队利用先进模型，包括基因工程改造的人类肠道干细胞（hISCs）和患者来源的异种移植（PDX），结合CRISPR/Cas9技术，确定了CRC的关键脆弱性。

Genome-wide SL screens revealed targets associated with common CRC driver mutations, particularly APC and KRAS. These findings were robustly validated. Notably, knock-out of the identified target selectively killed mutant patient-derived cells while sparing healthy intestinal stem cells, demonstrating a favorable therapeutic window..

全基因组SL筛选揭示了与常见的CRC驱动突变相关的目标，特别是APC和KRAS。这些发现得到了有力的验证。值得注意的是，敲除已识别的目标选择性地杀死了突变的患者来源细胞，同时保留了健康的肠道干细胞，展示了良好的治疗窗口。

Furthermore, we identified small-molecule inhibitors that block the activity of the newly discovered target. These compounds modulate downstream biomarkers and phenocopy the differential effects observed in our genetic studies, supporting this approach's translational potential.

此外，我们还鉴定了能够阻断这一新发现靶点活性的小分子抑制剂。这些化合物可以调节下游生物标志物，并在我们的遗传学研究中模拟观察到的差异效应，从而支持了这种方法的转化潜力。

Together, these results lay the groundwork for developing targeted therapies tailored to the genetic makeup of CRC tumors.

这些结果共同为开发针对CRC肿瘤基因组成的靶向疗法奠定了基础。

All posters are now available online and can be obtained from the conference site:

所有海报现在都可以在线获取，也可以从会议网站上获得：

https://www.aacr.org/

https://www.aacr.org/

Ryvu will also present at the

Ryvu 还将出席

2nd ADC Payload Summit in Boston,

波士顿第二届ADC有效载荷峰会，

MA, May 6-8, 2025. Krzysztof Brzózka, CSO of Ryvu Therapeutics, will give an oral presentation on

马萨诸塞州，2025年5月6日至8日。Ryvu Therapeutics的首席科学官克里斯托夫·布罗兹卡将进行口头报告。

'Exploring Next-Generation Payload Diversity Beyond Cytotoxics to Diversify Immune-oncology MOAs'

“探索超越细胞毒性药物的下一代有效载荷多样性，以实现免疫肿瘤学机制的多样化”

. The session will showcase Ryvu's innovative approach to expanding the diversity of payloads in antibody-drug conjugates (ADCs). Dr. Brzózka will discuss the company's approach to identifying new small-molecule payloads with conjugation potential, highlighting how matching target biology with the appropriate payload can optimize therapeutic outcomes.

会议将展示Ryvu在拓展抗体药物偶联物（ADC）有效载荷多样性方面的创新方法。Brzózka博士将讨论公司识别具有偶联潜力的新型小分子有效载荷的方法，重点介绍如何将目标生物学与适当的有效载荷相匹配以优化治疗效果。

This presentation reflects Ryvu's commitment to advancing ADC technologies and expanding immuno-oncology modalities for broader cancer treatment opportunities..

本演讲反映了 Ryvu 致力于推进 ADC 技术并扩展免疫肿瘤学模式，以创造更广泛的癌症治疗机会。

More information:

更多信息：

https://adc-payload.com/conference-day-two/

https://adc-payload.com/conference-day-two/

About

关于

Ryvu Therapeutics

鲁维治疗学

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel oncology therapies that address emerging targets in oncology. Internally discovered pipeline candidates at Ryvu use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules and antibody-drug conjugates directed at kinases, synthetic lethality, and immuno-oncology targets..

Ryvu Therapeutics是一家临床阶段的药物发现与开发公司，专注于针对肿瘤学新兴靶点的新型肿瘤疗法。Ryvu内部发现的候选管线利用了由癌症生物学新兴知识驱动的多样化治疗机制，包括针对激酶、合成致死性和免疫肿瘤学靶点的小分子和抗体药物偶联物。

Ryvu’s most advanced program is RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies. RVU120 is currently in Phase II development (i)  in combination with venetoclax for the treatment of patients with r/r AML – the RIVER-81 study, (ii) as a monotherapy for the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) – the REMARK study, (iii) as a monotherapy and in combination with ruxolitinib for the treatment of patients with myelofibrosis (MF) – the POTAMI-61 study.

Ryvu最前沿的项目是RVU120，一种选择性CDK8/CDK19激酶抑制剂，具有治疗血液系统恶性肿瘤的潜力。RVU120目前处于II期开发阶段：(i) 与维奈托克联合用于治疗r/r AML患者——RIVER-81研究，(ii) 作为单药治疗低风险骨髓增生异常综合征（LR-MDS）患者——REMARK研究，(iii) 作为单药及与鲁索替尼联合用于治疗骨髓纤维化（MF）患者——POTAMI-61研究。

Dapolsertib (MEN1703, SEL24) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is currently being investigated in a Phase II study in diffuse large B-cell lymphoma (DLBCL) – the JASPIS-01 study. RVU305, a potentially best-in-class, brain-permeable PRMT5 inhibitor aiming to treat multiple solid tumors, is currently in IND/CTA-enabling studies.

达泊司替尼（Dapolsertib，MEN1703，SEL24）是一种双重PIM/FLT3激酶抑制剂，已授权给美纳里尼集团，目前正在进行一项针对弥漫性大B细胞淋巴瘤（DLBCL）的II期研究——JASPIS-01研究。RVU305是一种潜在的同类最佳、可穿透血脑屏障的PRMT5抑制剂，旨在治疗多种实体瘤，目前正处于IND/CTA支持性研究阶段。

Ryvu Therapeutics is also engaged in oncology collaborations with BioNTech and Exelixis..

Ryvu Therapeutics还与BioNTech和Exelixis在肿瘤学领域展开合作。

The company was founded in 2007 and is headquartered in Kraków, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of the sWIG80 index.

该公司成立于2007年，总部位于波兰克拉科夫。Ryvu在华沙证券交易所上市，是sWIG80指数的成分股。

C

C

ontact

联系

Ryvu Therapeutics

Ryvu治疗学

Anna Wilk

安娜·威尔克

+48 532 698 425

+48 532 698 425

This email address is being protected from spambots. You need JavaScript enabled to view it.

这个电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Keywords: Ryvu Therapeutics; Preclinical data; RVU305; ONCO Prime; Next-generation ADCs; AACR Annual Meeting; Synthetic lethality; PRMT5 inhibitor; Colorectal cancer; Synthetic lethal targets; KRAS-driven tumors; ADC Payload Summit; Payload innovation; Antibody-drug conjugate; MTAP-deleted tumors; Immune checkpoint inhibitors; CRC (colorectal cancer); CRISPR/Cas9 technology; Patient-derived xenografts (PDXs); Small-molecule inhibitors; Immune-oncology MOAs; Target biology; Immuno-oncology; Kraków, Poland; Warsaw Stock Exchange; Immunoconjugates; Synthetic Lethal Mutations; Enzyme Inhibitors; Therapies, Investigational; Brain; Drug Discovery; Colorectal Neoplasms.

关键词：Ryvu Therapeutics；临床前数据；RVU305；ONCO Prime；下一代ADC；AACR年会；合成致死性；PRMT5抑制剂；结直肠癌；合成致死靶点；KRAS驱动的肿瘤；ADC有效载荷峰会；有效载荷创新；抗体药物偶联物；MTAP缺失肿瘤；免疫检查点抑制剂；CRC（结直肠癌）；CRISPR/Cas9技术；患者来源的异种移植模型（PDXs）；小分子抑制剂；免疫肿瘤学作用机制；靶点生物学；免疫肿瘤学；波兰克拉科夫；华沙证券交易所；免疫偶联物；合成致死突变；酶抑制剂；研究性疗法；脑；药物发现；结直肠肿瘤。

Source: Biotech Newswire

来源：生物技术新闻专线